Last reviewed · How we verify
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) (bnt162b2-2025-2026-recommended-sars-cov-2-strain)
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) (generic name: bnt162b2-2025-2026-recommended-sars-cov-2-strain) is a drug developed by Pfizer Inc.. It is currently in Phase 3 development.
At a glance
| Generic name | bnt162b2-2025-2026-recommended-sars-cov-2-strain |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BNT162b2 (LP.8.1)-ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID-19 (Phase 3)
- A Phase 3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b2 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants 12 Through 64 Years of Age (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) CI brief — competitive landscape report
- BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
What is BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)?
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) (bnt162b2-2025-2026-recommended-sars-cov-2-strain) is a pharmaceutical drug developed by Pfizer Inc..
Who makes BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)?
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)?
bnt162b2-2025-2026-recommended-sars-cov-2-strain is the generic (nonproprietary) name of BNT162b2 (2025/2026 recommended SARS-CoV-2 strain).
What development phase is BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) in?
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) is in Phase 3.